The key benefits
BAROSTIM THERAPY™ may offer resistant hypertension patients the ability to lower their cardiovascular risk by significantly lowering blood pressure.
BAROSTIM THERAPY™ may reduce blood pressure, helping the majority of patients reach their systolic blood pressure goal. 1* It is a neuromodulation therapy that triggers the body's main cardiovascular reflex to regulate blood pressure.
BAROSTIM THERAPY™ showed a significant reduction in blood pressure and heart rate in a randomized controlled trial with the first generation device and was corroborated in a 30-patient study with BAROSTIM NEO™.
Average responder reductions of 35 mmHg at month 12.1
Proportion of patients achieving SBP of ≤ 140 mmHg at month 6 and 12.1
* Over half (55%) of patients in the pivotal trial achieved goal SBP of ≤140 mmHg
1. Bisognano JD et al. Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension: Results From the Double-Blind, Randomized, Placebo-Controlled Rheos Pivotal Trial. JACC. 2011; 58: 7:765–773. 2. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the BAROSTIM NEO™ Trial. J Am Soc Hypertens. 2012;6(4):270-276.
* average of procedure time of 108 +/- 5 minutes